SEARCH:   Advanced

Blood, 1 January 2007, Vol. 109, No. 1, pp. 374-382. Prepublished online as a Blood First Edition Paper on August 29, 2006; DOI 10.1182/blood-2006-03-005769. This Article Full Text (PDF) All Versions of this Article: blood-2006-03-005769v1 109/1/374    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Meyer, R. G Articles by Herr, W. Search for Related Content PubMed PubMed Citation Articles by Meyer, R. G Articles by Herr, W. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 9, 2006 Accepted August 10, 2006 Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell depleted reduced-intensity transplantation Ralf G Meyer, Cedrik M Britten, Daniela Wehler, Klaus Bender, Georg Hess, Abdo Konur, Udo F Hartwig, Thomas C Wehler, Andrew J Ullmann, Chiara Gentilini, Lutz Uharek, Christoph Huber, Karin Kolbe, and Wolfgang Herr* Department of Medicine III, Johannes Gutenberg University, Mainz Department of Legal Medicine, Johannes Gutenberg University, Mainz Department of Medicine III, Charite, Campus Benjamin-Franklin, Berlin * Corresponding author; email: w.herr{at}3-med.klinik.uni-mainz.de. Allogeneic hematopoietic stem-cell transplantation (SCT) regimens incorporating the lymphocytotoxic CD52 antibody alemtuzumab demonstrate efficient engraftment and reduced graft-versus-host disease (GVHD). However, these protocols substantially impair post-transplant antiviral and antitumor immunity. To accelerate immune reconstitution after alemtuzumab-based reduced-intensity SCT, we administered prophylactic CD8-depleted donor lymphocyte infusions (DLIs) starting on day 60 and 120 after transplantation. DLIs were processed in an immunomagnetic good manufacturing practice depletion procedure resulting in a 2.5 to 6-log reduction in CD8 T cells. Of 23 high-risk patients with hematologic malignancies, 11 received a total of 21 CD8-depleted DLIs. Five patients developed transient grade I acute GVHD following transfer. Only two patients with HLA-C-mismatched donors showed grade II and III acute GVHD and subsequently progressed to limited chronic GVHD. Following DLIs, four patients with declining hematopoietic donor chimerism converted to full chimeras. A 2.1-fold median increase of circulating CD4 T cells was observed within 2 weeks after infusion. Non-DLI patients did not show a comparable rise in CD4 counts. Four patients demonstrated enhanced frequencies of cytomegalovirus-specific CD4 and CD8 T cells following transfer. Our results suggest that prophylactic CD8-depleted DLIs accelerate immune reconstitution after lymphodepleted HLA-matched SCT and carry a low risk of inducing severe GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity PNAS, March 11, 2008; 105(10): 3837 - 3842. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020